JP2017509602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509602A5 JP2017509602A5 JP2016552533A JP2016552533A JP2017509602A5 JP 2017509602 A5 JP2017509602 A5 JP 2017509602A5 JP 2016552533 A JP2016552533 A JP 2016552533A JP 2016552533 A JP2016552533 A JP 2016552533A JP 2017509602 A5 JP2017509602 A5 JP 2017509602A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- tle
- identity
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052721 tungsten Inorganic materials 0.000 claims 51
- 229910052698 phosphorus Inorganic materials 0.000 claims 28
- 229910052757 nitrogen Inorganic materials 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 229910052731 fluorine Inorganic materials 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 102000029301 Protein S Human genes 0.000 claims 3
- 108010066124 Protein S Proteins 0.000 claims 3
- 229940096437 Protein S Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- FRJNIHLOMXIQKH-UHFFFAOYSA-N 1-amino-15-oxo-4,7,10-trioxa-14-azaoctadecan-18-oic acid Chemical compound NCCCOCCOCCOCCCNC(=O)CCC(O)=O FRJNIHLOMXIQKH-UHFFFAOYSA-N 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 230000023555 blood coagulation Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- -1 X1001 is A Proteins 0.000 claims 1
- 101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000052932 human PROS1 Human genes 0.000 claims 1
- 229940099815 human protein s Drugs 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946103P | 2014-02-28 | 2014-02-28 | |
| US61/946,103 | 2014-02-28 | ||
| PCT/US2015/018041 WO2015131061A1 (en) | 2014-02-28 | 2015-02-27 | Peptides and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509602A JP2017509602A (ja) | 2017-04-06 |
| JP2017509602A5 true JP2017509602A5 (enExample) | 2018-03-01 |
| JP6711761B2 JP6711761B2 (ja) | 2020-06-17 |
Family
ID=52633723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552533A Active JP6711761B2 (ja) | 2014-02-28 | 2015-02-27 | ペプチド及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9447147B2 (enExample) |
| EP (1) | EP3110841B1 (enExample) |
| JP (1) | JP6711761B2 (enExample) |
| KR (1) | KR20160126075A (enExample) |
| CN (1) | CN106232615B (enExample) |
| AU (1) | AU2015222846B2 (enExample) |
| BR (1) | BR112016019484A2 (enExample) |
| CA (1) | CA2939658C (enExample) |
| EA (1) | EA201691749A1 (enExample) |
| ES (1) | ES2873956T3 (enExample) |
| IL (1) | IL247448B (enExample) |
| MX (1) | MX385558B (enExample) |
| PH (1) | PH12016501608B1 (enExample) |
| SG (2) | SG11201607067TA (enExample) |
| WO (1) | WO2015131061A1 (enExample) |
| ZA (1) | ZA201605518B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021268943A1 (en) | 2020-05-05 | 2022-11-24 | Vega Therapeutics, Inc. | Protein S antibodies, methods of making and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5321123A (en) * | 1991-07-02 | 1994-06-14 | The Scripps Research Institute | Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods |
| SE9604378D0 (sv) * | 1996-11-27 | 1996-11-27 | Tac Ab | Methods and reagents for determining protein S |
| EP1446152A1 (en) * | 2001-11-09 | 2004-08-18 | Novo Nordisk A/S | Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors |
| WO2011115712A2 (en) * | 2010-03-19 | 2011-09-22 | Baxter International Inc | Tfpi inhibitors and methods of use |
| US9073990B2 (en) * | 2010-04-05 | 2015-07-07 | Bar-Llan University | Protease-activatable pore-forming polypeptides |
| SI2827883T1 (sl) | 2012-03-21 | 2019-08-30 | Baxalta GmbH | Inhibitorji TFPI in postopki uporabe |
| CN104211799B (zh) * | 2013-05-29 | 2017-12-26 | 成都渊源生物科技有限公司 | 人源egf结构域蛋白及其应用 |
-
2015
- 2015-02-27 SG SG11201607067TA patent/SG11201607067TA/en unknown
- 2015-02-27 MX MX2016011174A patent/MX385558B/es unknown
- 2015-02-27 JP JP2016552533A patent/JP6711761B2/ja active Active
- 2015-02-27 CA CA2939658A patent/CA2939658C/en active Active
- 2015-02-27 KR KR1020167026913A patent/KR20160126075A/ko not_active Ceased
- 2015-02-27 AU AU2015222846A patent/AU2015222846B2/en active Active
- 2015-02-27 EA EA201691749A patent/EA201691749A1/ru unknown
- 2015-02-27 WO PCT/US2015/018041 patent/WO2015131061A1/en not_active Ceased
- 2015-02-27 SG SG10201807066UA patent/SG10201807066UA/en unknown
- 2015-02-27 CN CN201580011074.8A patent/CN106232615B/zh not_active Expired - Fee Related
- 2015-02-27 ES ES15709067T patent/ES2873956T3/es active Active
- 2015-02-27 US US14/634,028 patent/US9447147B2/en active Active
- 2015-02-27 EP EP15709067.1A patent/EP3110841B1/en active Active
- 2015-02-27 BR BR112016019484A patent/BR112016019484A2/pt not_active Application Discontinuation
- 2015-02-27 IL IL247448A patent/IL247448B/en unknown
- 2015-02-27 PH PH1/2016/501608A patent/PH12016501608B1/en unknown
-
2016
- 2016-08-10 ZA ZA2016/05518A patent/ZA201605518B/en unknown
- 2016-08-19 US US15/242,002 patent/US10124033B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015134758A5 (enExample) | ||
| JP2013127002A5 (enExample) | ||
| JP2010515686A5 (enExample) | ||
| ES2661500T3 (es) | Variantes de HMGB1 y sus usos | |
| JP2010513506A5 (enExample) | ||
| CN104984319B (zh) | Tfpi抑制剂和使用方法 | |
| JP2011530599A5 (enExample) | ||
| HRP20161416T1 (hr) | Novi transportni konstrukti i transportne nosive konjugirane molekule | |
| JP2011502964A5 (enExample) | ||
| JP2011502479A5 (enExample) | ||
| JP2012126750A5 (enExample) | ||
| JP2015530404A5 (enExample) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| CN109311983B (zh) | 人源化抗clever-1抗体及其用途 | |
| JP2012509902A5 (enExample) | ||
| JP2019108360A5 (enExample) | ||
| JP2017531613A5 (enExample) | ||
| JP2010514779A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2010519180A5 (enExample) | ||
| JP2014526881A5 (enExample) | ||
| JP2006502702A5 (enExample) | ||
| Al Musaimi | FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond | |
| JP2016536357A5 (enExample) |